CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease-Reference-Cited by-同舟云学术

CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease

Published:2012-10-29 Issue:11 Volume:42 Page:3062-3072
ISSN:0014-2980
Container-title:European Journal of Immunology
language:en
Short-container-title:Eur. J. Immunol.

Author:

Doherty Glen A.¹,Bai Aiping¹,Hanidziar Dusan¹,Longhi Maria S.¹,Lawlor Garrett O.¹,Putheti Prabhakar¹,Csizmadia Eva¹,Nowak Martina¹,Cheifetz Adam S.¹,Moss Alan C.¹,Robson Simon C.¹

Affiliation:

1. Division of Gastroenterology; Beth Israel Deaconess Medical Center & Harvard Medical School; Boston USA

Funder

NIH

National Center for Research Resources

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/eji.201242623/fullpdf

Reference29 articles.

1. From the cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease;Friedman;Proc. Natl. Acad. Sci. USA,2009

2. Control of IFN-alphaA by CD73: implications for mucosal inflammation;Louis;J. Immunol.,2008

3. ATP drives lamina propria T(H)17 cell differentiation;Atarashi;Nature,2008

4. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression;Deaglio;J. Exp. Med.,2007

5. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease;Odashima;Gastroenterology,2005

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of the role of purinergic signaling and insights into its role in cancer therapy;Pharmacology & Therapeutics;2024-10

2. Ectonucleotidases in Ischemia Reperfusion Injury: Unravelling the Interplay With Mitochondrial Dysfunction in Liver Transplantation;Transplantation Proceedings;2024-09

3. NSCLC patients with oligo-metastatic brain disease show an altered CD4 T-cells immune profile;2024-04-14

4. Low Pretreatment CD4+:CD8+ T Cell Ratios and CD39+CD73+CD19+ B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma;International Journal of Molecular Sciences;2023-08-08

5. Review immune response of targeting CD39 in cancer;Biomarker Research;2023-06-07